Drug recall · March 15, 2023
Metformin hydrochloride Extended-Release Tablets recall
Why: CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Metformin hydrochloride Extended-Release Tablets, 1000 mg, 60-count bottle, RX only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054 USA, NDC 00591-2720-60
- Lots / codes
Lot #: 1410946A; Exp. 06/2023
- Quantity
- 12,044 Bottles
- Company
- Teva Pharmaceuticals USA Inc, Parsippany, NJ
- Distribution
- CA
- Initiated
- February 22, 2023 · Voluntary: Firm initiated
- Classified
- March 7, 2023
- Reported
- March 15, 2023
- Ended
- December 6, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Metformin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.